Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, run-in, Multi-center, Phase II Study of Nivolumab Combined With Ipilimumab and Guadecitabine or Nivolumab Combined With Ipilimumab in Melanoma and NSCLC Patients Resistant to Anti-PD-1/PD-L1 (NIBIT-ML1)

NCT04250246 is registered in ClinicalTrials.gov with Italian Network for Tumor Biotherapy Foundation as lead sponsor.

NCT NCT04250246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04250246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, run-in, Multi-center, Phase II Study of Nivolumab Combined With Ipilimumab and Guadecitabine or Nivolumab Combined With Ipilimumab in Melanoma and NSCLC Patients Resistant to Anti-PD-1/PD-L1 (NIBIT-ML1)
Lead sponsor
Italian Network for Tumor Biotherapy Foundation
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2020
Completion date
March 31, 2025
Enrollment
184 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, non small cell lung cancer